Omeros Corporation is a commercial-stage biotechnology company that discovers and develops protein and small-molecule therapeutics targeting complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's lead commercial product, YARTEMLEA (narsoplimab), is an FDA-approved selective MASP-2 inhibitor for hematopoietic stem cell transplant-associated thrombotic microangiopathy that offers the advantage of preserving critical host-defense functions while carrying no boxed warning or complex pre-treatment requirements. The company generates revenue from direct YARTEMLEA sales through its own commercial infrastructure targeting major transplant centers, from partnership milestones and royalties (including a significant agreement with Novo Nordisk for development and commercialization of the MASP-3 inhibitor zaltenibart), and from its clinical-stage pipeline programs in complement inhibition, oncology, and addiction disorders, while relying on contract manufacturers for drug production and supply chain management.